

Contents

Strategies in Psychotropic Drug Innovation

Receptor Subtypes and Endogenous Ligands: Rational Tools in the Search for Psychotropic Drugs? C. BRAESTRUP and P. H. ANDERSEN. With 1 Figure	3
Histamine H ₃ Receptors in the Brain: Potent and Selective Ligands. J. C. SCHWARTZ, J. M. ARRANG, M. GARBARG, and H. POLLARD. With 3 Figures	10
Targets for Neurotransmitter Receptor Research Using PET Scan: The Neuroleptic Binding Site. J. C. BARON, J. L. MARTINOT, H. CAMBON, J. P. BOULENGER, M. F. POIRIER, V. CAILLARD, J. BLIN, J. D. HURET, C. LOC'H, and B. MAZIERE. With 4 Figures	20
The Potential of Positron-Emission Tomography for Pharmacokinetic and Pharmacodynamic Studies of Neuroleptics. L. FARDE, F.-A. WIESEL, L. NILSSON, and G. SEDVALL. With 2 Figures ..	32
Neurotransmitter Interactions as a Target of Drug Action. W. Z. POTTER, J. K. HSIAO, and H. ÅGREN. With 1 Figure	40
E-10-Hydroxynortriptyline: Effects and Disposition of a Potential Novel Antidepressant. L. BERTILSSON, M.-L. DAHL-PUUSTINEN, and C. NORDIN. With 3 Figures .	52
Molecular Graphics of Antidepressant Drugs and Metabolites. S. G. DAHL, Ø. EDVARSEN, and E. HEIMSTAD. With 5 Figures	60
Negative Symptoms in Schizophrenia: A Target for New Drug Development. H. Y. MELTZER and J. ZUREICK	68

Clinical Significance of Receptor-Selective Drugs

Clinical Effects of Selective Serotonin Reuptake Inhibitors. P. BECH	81
Effects of Serotonergic Agonists on Neuroendocrine Responses of Rhesus Monkeys and Patients with Depression and Anxiety Disorders. G. R. HENINGER, D. S. CHARNEY, L. H. PRICE, P. DELGADO, S. WOODS, and W. GOODMAN	94
Theoretical and Practical Implications of a Controlled Trial of an α_2 -Adrenoceptor Antagonist in the Treatment of Depression. S. A. MONTGOMERY	105
Selective Dopamine D ₁ and D ₂ Receptor Antagonists. J. HYTTTEL, J. ARNT, and M. VAN DEN BERGHE. With 3 Figures	109
Animal Pharmacology of Raclopride, a Selective Dopamine D ₂ Antagonist. H. HALL, S. O. ÖGREN, C. KÖHLER, and O. MAGNUSSON. With 5 Figures ..	123
Benzodiazepine Receptor Subtypes and Their Possible Clinical Significance. W. SIEGHART	131

Pharmacogenetics in Psychopharmacology

Genetic Polymorphisms of Drug-Metabolizing Enzymes: Molecular Mechanisms. U. A. MEYER, U. ZANGER, R. SKODA, and D. M. GRANT. With 1 Figure ..	141
Genetic Polymorphism in Drug Oxidation. W. KALOW	148
The Use of Human Liver Banks in Pharmacogenetic Research. C. VON BAHR, F. P. GUENGERICH, G. MOVIN, and C. NORDIN. With 4 Figures	163
Inhibitors of the Microsomal Oxidation of Psychotropic Drugs: Selectivity and Clinical Significance. L. F. GRAM and K. BRØSEN. With 3 Figures	172
Pharmacogenetics of Antidepressants. F. SJÖQVIST. With 9 Figures	181

**Pharmacokinetic and Clinical Significance of Genetic Variability
in Psychotropic Drug Metabolism.**

K. BRØSEN and L. F. GRAM. With 5 Figures 192

**Inhibition of Desipramine 2-Hydroxylation by Quinidine and Quinine
in Rapid and Slow Debrisoquine Hydroxylators.**

E. SPINA, E. STEINER, E. DUMONT, and R. DAHLQVIST. With 1 Figure 201

Debrisoquine Oxidation Phenotype in Psychiatric Patients.

J. BENÍTEZ, B. PIÑAS, M. A. GARCÍA, C. MARTÍNEZ, A. LLERENA,
and J. COBALEDA. With 2 Figures 206

Role of Pharmacogenetics in Drug Development.

L. P. BALANT and A. E. BALANT-GORGIA 211

Clinical Significance of Pharmacokinetic Variability

**Clinical Implications of the Pharmacokinetics of
Tricyclic Antidepressants.**

J. C. NELSON, C. MAZURE, and P. I. JATLOW 219

Detection of Populations at Risk Using Drug Monitoring Data.

A. E. BALANT-GORGIA, M. GEX-FABRY, and L. P. BALANT 228

**Hydroxy Metabolites of Tricyclic Antidepressants:
Evaluation of Relative Cardiotoxicity.**

B. G. POLLOCK and J. M. PEREL. With 1 Figure 232

**Therapeutic Drug Monitoring of Tricyclic Antidepressants:
A Means of Avoiding Toxicity.**

S. H. PRESKORN 237

**Neuroleptic Drug Levels in Erythrocytes and in Plasma:
Implications for Therapeutic Drug Monitoring.**

D. L. GARVER. With 3 Figures 244

**Active Metabolites of Neuroleptics in Plasma and CSF:
Implications for Therapeutic Drug Monitoring.**

E. MÄRTENSSON and G. NYBERG. With 4 Figures 257

Hydroxyhaloperidol and Clinical Outcome in Schizophrenia.

A. C. ALTAMURA, M. MAURI, R. CAVALLARO, M. G. REGAZZETTI,
and S. R. BAREGGI. With 3 Figures 263

Plasma Level Monitoring for Maintenance Neuroleptic Therapy. S. R. MARDER, T. VAN PUTTEN, and M. ARAVAGIRI. With 6 Figures	269
---	-----

Perphenazine Serum Levels in Patients on Standard Doses. F. HAFFNER. With 1 Figure	280
---	-----

Dose-Finding Problems with Psychotropic Drugs

From Animal Experiments to Clinical Dosing: Some Aspects of Preclinical Development of Antidepressants. A. DELINI-STULA. With 1 Figure	287
--	-----

Evaluation of Clinical and Biological Parameters in Healthy Volunteers: More than Pharmacokinetics and Side Effects? A. J. PUECH, P. DANJOU, D. WAROT, G. BENSIMON, and L. LACOMBLEZ . .	296
--	-----

Dose Finding and Serum Concentrations of Neuroleptics in the Treatment of Schizophrenic Patients. F.-A. WIESEL, G. ALFREDSSON, and E. JÖNSSON. With 4 Figures	303
---	-----

Post-Marketing Surveillance of Psychotropic Drugs. R. BRINKMANN. With 1 Figure	311
---	-----

List of Participants	317
---------------------------------------	------------

Subject Index	325
--------------------------------	------------